Search Results

1 - 10 of 92 items :

Clear All

REFERENCES 1. GRAEBER KE, OLSEN NJ. Th17 cell cytokine secretion profile in host defense and autoimmunity . Inflamm Res. 2012; 61 (2):87-96. 2. HYMOWITZ SG, FILVAROFF EH, YIN JP, LEE J, CAI L, RISSER P, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding . EMBO J. 2001; 20 :5332–41. 3. TANASESCU C, BĂLĂNESCU E, BĂLĂNESCU P, OLTEANU R, BADEA C, GRANCEA C, et al. IL-17 in cutaneous lupus erythematosus . Eur J Intern Med. 2010; 21 (3):202-7. 4. BLAUVELT A. T-helper 17 cells in

Inflammation in the Tumor Microenvironment. Frontiers in Immunology 2016;7:682. 9. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, Martin MU. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J Immunol 2011;187:1609-1616. 10. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI, Spriggs MK. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995;3:811-821. 11. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P

L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S. Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204:1849-1861. 6. Hammerich L, Heymann F, Tacke F. Role of IL-17 and Th17 cells in liver diseases. Clinical and Developmental Immunology 2011; 2011:345803. 7. Ivanova EA, Orekhov AN. T helper lymphocyte subsets and plasticity in autoimmunity and cancer: an overview. BioMed Research International 2015, article ID 327470, 9 pages 8. Golubovskaya V, Wu L. Different

References 1. BREMBILLA NC, CHIZZOLINI C. T cell abnormalities in systemic sclerosis with a focus on Th17 cells. Eur Cytokine Netw. 2012; 23(4):128-39. 2. ZHU J, PAUL WE. CD4 T cells: fates, functions, and faults. Blood. 2008; 112(5):1557-69. 3. PAVLOVIC V, DIMIC A, MILENKOVIC S, KRTINIC D. Serum levels of IL-17, IL-4, and INFγ in Serbian patients with early rheumatoid arthritis. J Res Med Sci. 2014; 19(1):18-22. 4. BĂLĂNESCU P, BĂLĂNESCU E, TĂNĂSESCU C, NICOLAU A, TĂNĂSESCU R, GRANCEA C, VAGU C, RUŢĂ S, BLEOŢU C. T helper 17 cell population in lupus

.1155/2014/149185. 5. Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts). Clin Ter. 2006; 157: 377-86. 6. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004; 75: 163-89. 7. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010; 10: 479-489. 8. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from

; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 Suppl 86: 8-160. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Growth Factor Rev 2003; 14 (2): 155-74. Miyamoto M, Prause O, Sjostrand M, et al. Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J Immunol 2003; 170 (9): 4665-72. Zou GM, Tam YK. Cytokines in the generation and maturation of dendritic cells

;4:21-30. 8 Allen RL, Trowsdale J. Recognition of classical and heavy chain form of HLA-B27 by leukocyte receptor. Curr Mol Med 2004; 4(1):59-65. 9 Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010;121:906-915. 10 Ekinci NS, Alpsoy E, Karakas AA, Yilmaz SB, Yegin O. IL-17A has an important role in the acute attacks of Behçet’s disease. J Invest Dermatol 2010;130(8):2136-2138.

-tosevere plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study . British Journal of Dermatology. 2013; 168 (2):412-21. 51. LANGLEY RG, ELEWSKI BE, LEBWOHL M, et al . Secukinumab in plaque psoriasis—results of two phase 3 trials . New England Journal of Medicine. 2014; 371 (4):326-38. 52. FALA L. Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis. American Health & Drug Benefits . 2016; 9 (Spec Feature):60. 53. Summary of product characteristics Talz. [Accessed 22

. Arthritis Rheum 2009; 60: 1472–83. 25. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008; 127: 385–93. 26. Lee JY, Park JK, Lee EY, Lee EB, Song YW. Circulating exosomes from patients with systemic lupus erythematosus induce an proinflammatory immune response. Arthritis Res Ther 2016; 18: 264. 27. Dolff S, Quandt D, Wilde B, Feldkamp T, Hua F, Cai X, et al. Increased expression of costimulatory markers CD134 and

index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005;210:194-9. 5. Ariza ME, Williams MV, Wong HK. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application. Clin Immunol 2013;146:131-9. 6. Laggner U, Di Meglio P, Perera GK, Hundhausen C, Lacy KE, Ali N, et al. Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis. J Immunol 2011;187:2783-93. 7. Kawaguchi M, Takahashi D, Hizawa N, Suzuki S, Matsukura S, Kokubu F, et al. IL-17F